Who is sponsoring NCT01087814?

NCT01087814 is sponsored by University of Minnesota.

What condition does NCT01087814 study?

NCT01087814 studies HIV, HIV Infections.

What drugs are being tested in NCT01087814?

Interventions: Efavirenz, Over-encapsulated efavirenz.

What is the status of NCT01087814?

NCT01087814 is currently COMPLETED.

Last reviewed 2017-01-26 · How we verify

Effect of Encapsulation Upon Efavirenz Pharmacokinetics

NCT01087814 Phase 4 COMPLETED Results posted

We are studying if putting a gel capsule over a standard HIV drug changes the ability of the body to absorb the drug. This is important because we want to be able to study new HIV drugs against the most common drugs used today and the most common is Sustiva, which is also called efavirenz. We will give you Sustiva every day for 5 days and draw blood to see how much is absorbed. Then we will give you Sustiva that has a gel capsule over it for 5 days and we will draw blood to see how much is absorbed.

Details

Lead sponsor	University of Minnesota
Phase	Phase 4
Status	COMPLETED
Enrolment	16
Start date	2010-02
Completion	2011-09

Conditions

HIV
HIV Infections

Interventions

Efavirenz
Over-encapsulated efavirenz

Primary outcomes

Serum Levels of Efavirenz — 5th day of taking drug
Serum levels of efavirenz were measured on the fifth day of taking efavirenz (tablet) and the fifth day of taking an overencapsulated efavirenz.

Countries

United States